WHO Prequalifies First Malaria Treatment for Newborns and New Diagnostic Tests

WHO Closes Critical Treatment Gap with First Malaria Medicine for Newborns

The World Health Organization (WHO) has announced a landmark advancement in global health with the prequalification of the first malaria treatment specifically developed for newborns and young infants. This move addresses a long-standing void in pediatric care, providing a safe, quality-assured option for one of the most vulnerable and underserved patient populations in the world.

Until now, infants weighing between two and five kilograms—the very youngest malaria patients—had to be treated with formulations intended for older children. This practice significantly increased the risk of toxicity, side effects, and dosing errors. The new prequalified treatment, artemether-lumefantrine, is designed specifically for this weight class, ensuring that the most fragile patients receive the precise dosage required for recovery.

This designation is more than a medical milestone. it’s a logistical breakthrough. WHO prequalification allows for public sector procurement, which is essential for closing the treatment gap for approximately 30 million babies born annually in malaria-endemic regions of Africa.

“For centuries, malaria has stolen children from their parents, and health, wealth and hope from communities,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. “But today, the story is changing. New vaccines, diagnostic tests, next-generation mosquito nets and effective medicines, including those adapted for the youngest, are helping to turn the tide.”

Solving the “Invisible” Parasite: New Diagnostic Tests

While the new treatment saves lives at the bedside, WHO is also tackling a growing crisis in diagnosis. On April 14, 2026, the organization prequalified three new rapid diagnostic tests (RDTs) to combat emerging parasite mutations.

The challenge lies in the biology of the P. Falciparum parasite. Most common RDTs detect a protein called HRP2. However, studies across 46 countries have revealed that some malaria strains have lost the gene responsible for producing this protein. This makes the parasite effectively “invisible” to standard tests, resulting in false-negative results.

The impact of these diagnostic failures has been devastating. In parts of the Horn of Africa, up to 80% of cases were missed, leading to severe illness, delayed treatment, and death. The new prequalified tests solve this by targeting pf-LDH, a different parasite protein that cannot be easily shed.

To protect vulnerable communities, WHO now recommends that countries transition to these alternative RDTs whenever more than 5% of malaria cases are missed due to pf-hrp2 deletions.

The Global Landscape: Progress Amidst Stalling Gains

These breakthroughs arrive as part of the 2026 World Malaria Day campaign, themed “Driven to End Malaria: Now We Can. Now We Must.” While the new tools provide hope, the broader data reveals a complex struggle.

According to the World Malaria Report 2025, global progress is currently stalling. In 2024, there were an estimated 282 million cases and 610,000 deaths—an increase over 2023 figures. The WHO attributes this stagnation to several critical challenges:

• Rising drug and insecticide resistance.
• Diagnostic failures (such as the HRP2 deletions).
• Significant reductions in international development assistance.

Despite these headwinds, the long-term trajectory remains positive. Since 2000, an estimated 14 million lives have been saved and 2.3 billion infections prevented. Today, 47 countries are certified malaria-free, and 37 countries reported fewer than 1,000 cases in 2024.

Key Takeaways for Global Health

The current fight against malaria is characterized by a shift toward precision medicine and innovative prevention. Here are the most critical developments:

• Targeted Pediatrics: Artemether-lumefantrine now provides a safe dosing standard for infants weighing 2–5 kg.
• Diagnostic Evolution: The shift toward pf-LDH tests ensures that “invisible” strains of P. Falciparum are detected.
• Preventative Scale: Malaria vaccines are now being rolled out in 25 countries.
• Next-Gen Protection: Next-generation mosquito nets now account for 84% of all new nets distributed.

Ending malaria is no longer a distant dream, but it requires sustained political and financial commitment. By equipping healthcare providers with the right tools for the youngest patients and the most elusive parasites, the global community is moving closer to a malaria-free future.